Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2017

View Archived Issues

ZFPM2 found as a gene for primary ovarian insufficiency

Pfizer announces European approval of the Meningococcal Group B vaccine Trumenba

VesiGel shows promise as alternative to resection in nonmuscle-invasive bladder cancer

Nippon Boehringer Ingelheim and Kobe University enter diabetes agreement

FDA clears IND for LOXO-195

Novel bile acid receptor agonist BAR-704 limits experimental liver fibrosis

Four phase III studies of bictegravir/emtricitabine/tenofovir alafenamide meet primary endpoints

Sanofi and ImmunoGen amend cancer immunotherapy agreements

University of Michigan begins phase I trial of oral heptapeptide KSP-910638G

Inspyr Therapeutics to merge with Lewis and Clark Pharmaceuticals to create novel integrated company

Asana BioSciences advances phase I/II study of ASN-002

i2 Pharmaceuticals acquires antibody and protein therapeutics portfolio

BAMBI inhibition is beneficial in autoimmune diseases

C1orf198 found to be a predictor of metastasis in bladder cancer

Wockhardt discloses compounds for treating bacterial infections

Daewoong Pharmaceutical presents Nav1.7 channel blockers

TD-139 well tolerated and affects biomarkers in idiopathic pulmonary fibrosis trial

AstraZeneca identifies MAPK1 inhibitors

Eisai presents AMPA receptor antagonists

Fennec launches European Named Patient Program for sodium thiosulfate

Zhejiang Hisun Pharmaceutical divulges estrogen receptor alpha modulators

FDA gives rare pediatric disease designation to EB-101 from Abeona

Ligand Pharmaceuticals enters agreement with xCella Biosciences

Phase III RANGE urothelial cancer study of ramucirumab meets primary endpoint

Array and Ono partner to develop and commercialize binimetinib and encorafenib